ICAM1 and neoplasm: To validate the role of ICAM-1 in controlling tumor cell sensitivity to killing by CTLs, we disrupted ICAM1 in three tumor cell lines expressing low, medium, and high ICAM-1 (HCT 116, Panc-1 and UACC-257, respectively) using two different sgRNAs.